| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2134019 | Experimental Hematology | 2011 | 12 Pages |
Abstract
SNDX-275 has antiproliferative activity in HL cell lines, involving several mechanisms: induction of apoptosis, regulation of cytokines and chemokines, and alteration of cancer/testis antigens. Clinical investigation of SNDX-275 alone or in combination with Bcl-2 inhibitors is warranted in patients with HL. Phase 2 studies with SNDX-275 in HL are ongoing, and future clinical studies should investigate combinations with SNDX-275.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ádám Jóna, Noor Khaskhely, Daniela Buglio, Jessica A. Shafer, Enrico Derenzini, Catherine M. Bollard, L. Jeffrey Medeiros, Árpád Illés, Yuan Ji, Anas Younes,